Focused Issue on Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting

Posted On 2019-08-13 09:29:40

This focused issue about the Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting is edited by Dr. Sanja Dacic, Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.

Dr. Sanja Dacic is a Thoracic Pathologist and Professor of Pathology at the University of Pittsburgh Medical Center. Her clinical work includes all diagnostic aspects of neoplastic and non-neoplastic thoracic pathology including lung transplantation. Her research work is primarily focused on prognostic and predictive biomarkers in lung cancer and malignant mesotheliomas. She is a member of the International Association for the Study of Lung Cancer (IASLC) Pathology Committee, International Mesothelioma Interest Group, and the US and Canadian Mesothelioma Panel. She currently serves as a vice-president of the Pulmonary Pathology Society. She held leadership positions at the United States and Canadian Academy of Pathology including member of the Education Committee (2011-2015), member of the Board of Directors (2015-2018), and chair of the Young Investigator Awards Committee (2015-2018). She is a co-author of the 4th edition of WHO classification of the lung tumors, the CAP/AMP/IASLC guideline for molecular testing in lung carcinoma and the diagnostic mesothelioma guideline. She is the Deputy Chief Editor for Archives of Pathology and Laboratory Medicine.

Focused issue outline:

  1. Controversies and challenges in the histologic subtyping of lung adenocarcinoma
    Kelly Butnor, Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA
  2. Clinical significance of spread through airspaces (STAS)
    Mari Mino-Kenudson, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
  3. Multiple faces of large cell neuroendocrine carcinoma
    Natasha Rekhtman, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  4. Lung cancer biomarker testing-perspective from Asia
    Yasushi Yatabe, Department of Pathology, National Cancer Center, Tokyo, Japan
    Noriko Motoi, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
  5. Lung cancer biomarker testing-perspective from Europe
    Erik Thunnissen, Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands
  6. Molecular testing for predictive biomarkers in lung cancer on cytology specimens
    Sinchita Roy-Chowdhuri, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  7. PD-L1 harmonization studies
    Sylvie Lantuejoul, Department of Biopathology, National referent center MESOPATH-National Clinicobiologic Databasis MESOBANK, Cancer Center of Léon Bérard, Lyon, France; Institute for Advanced Biosciences-University Grenoble Alpes, Grenoble, France
  8. Update on pathologic diagnosis of malignant mesothelioma
    Aliya Husain, Department of Pathology, University of Chicago, Chicago, IL, USA
  9. Clinical significance of histologic subtyping of malignant mesothelioma
    Luka Brcic, Medical University of Graz, Diagnostic and Research Institute of Pathology, Graz, Austria
  10. Diagnosis of pleural mesothelioma on cytology
    Katalin Dobra, Karolinska Institutet, Department of Laboratory Medicine, Division of Pathology, Karolinska University Hospital, Stockholm, Sweden